Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Roche has kicked off TARBELA-AD, a global Phase 2 trial testing RG6434 — an oral NLRP3 inflammasome inhibitor — in adults with early symptomatic Alzheimer's disease. The trial aims to see whether quieting neuroinflammation can slow cognitive decline alongside existing amyloid-clearing therapies. About 450 participants across 17 countries will be enrolled over a 72-week treatment period.
Roche has launched TARBELA-AD, a global Phase 2 trial testing whether targeting neuroinflammation can slow Alzheimer's disease (AD) progression. The trial evaluates RG6434, an investigational oral NLRP3 inflammasome inhibitor, in roughly 450 adults aged 50–90 with biomarker-confirmed amyloid pathology and early symptomatic AD. Participants are randomized 1:1:1 to a high dose, low dose, or placebo over 72 weeks, spanning 17 countries, with primary completion estimated for November 2029.
The scientific rationale centers on the NLRP3 inflammasome — a microglial immune hub that, when activated by amyloid-beta, triggers release of pro-inflammatory cytokines IL-1β and IL-18, which in turn promote tau phosphorylation and neuronal damage. Autopsy data confirm NLRP3 is upregulated in Alzheimer's brains, and a 2026 analysis of CSF samples from Roche's GRADUATE Phase 3 program found that higher baseline NLRP3-related markers correlated with faster cognitive decline.
Key Takeaways:
Why it matters: Most approved AD therapies focus on clearing amyloid — but amyloid removal alone hasn't fully stopped disease progression. TARBELA-AD represents a complementary strategy, pairing amyloid clearance with neuroinflammation suppression, potentially addressing a critical missing piece in the Alzheimer's treatment puzzle.